All articles by Taylor Mixides (Drug Target Review) – Page 3
-
ArticleBrain macrophage in Parkinson's disease neuroinflammation
A growing body of evidence pinpoints neuroinflammation as a pivotal factor driving brain-related pathogenesis. Yet, a crucial question lingers: among the various immune cell groups residing within the brain, which one orchestrates this inflammatory reaction?
-
ArticleDecoding cell therapy variants with Dr Andy Bader
The field of cell therapy has emerged as a beacon of hope, promising transformative treatments for various diseases. Diving into the intricacies of this domain, this exclusive interview explores the distinctions between two key approaches – autologous and allogeneic cell therapies. We look at the nuances of cell sourcing, preclinical ...
-
ArticleWomen in Stem with Theonie Anastassiadis
Join us for our monthly Women in STEM series where we showcase and celebrate the achievements of inspiring women in the field. This month we interview Theonie Anastassiadis, Cofounder & Chief Innovation Officer of Alltrna and Senior Principal of Flagship Pioneering. As a senior principal at Flagship Pioneering, Theonie conceives, ...
-
ArticleTherapeutic frontiers: the potential of RRx-001 and AdAPT-001
Meet RRx-001 (nibrozetone) and AdAPT-001—two cutting-edge compounds crafted by EpicentRx. In this Q&A session with Dr Bryan Oronsky, Chief Development Officer at EpicentRx, we discover novel mechanisms, diverse applications, and game-changing impact on cancer treatment and beyond.
-
ArticleCancer immunotherapy: GDF-15's role in Anti-PD-1 resistance
In this interview with Christine Schuberth-Wagner, Chief Scientific Officer at CatalYm, we discover research uncovering a central factor contributing to anti-PD-1 resistance in cancer immunotherapy.
-
ArticleHuntington's disease and potential therapies
In this exclusive interview with Young Kwon, CEO of Alchemab, we discuss new platforms that are revolutionising how researchers identify naturally occurring antibodies in resilient individuals, opening up new possibilities for the development of disease-modifying therapies.
-
ArticleHPV-associated head and neck cancers identified
Human papillomavirus (HPV)-associated head and neck cancers, specifically head and neck squamous cell carcinoma (HNSCC), are on the rise worldwide. Yet, the factors contributing to these tumours and their varying responses to treatment remain poorly understood.
-
ArticleThe potential of FcγRIIB in immunotherapy
We exclusively interview Dr Ali Roghanian, Associate Professor at the University of Southampton, UK, Ali is a leading researcher at the forefront of immunotherapy advancements. With a keen focus on the inhibitory IgG FcγRIIB receptor, join us as we dive into Ali’s findings, showcasing the complexities of FcγRIIB and its ...
-
ArticleSERS-artificial intelligence method for early detection of cancer
Scientists have developed a promising new method to detect cancer at very early stages during routine health screens, paving way for improved treatment and recovery.
-
ArticleAgeing and cancer-causing gene: researchers uncover a link
Researchers from UPMC Children's Hospital of Pittsburgh and the University of Pittsburgh School of Medicine have made a discovery linking the notorious cancer-causing gene, Myc, to the process of ageing.
-
Article
Advancing vaccine design: potential of peptide mimicry
A new discovery presents a bioinformatic approach for improving vaccine effectiveness against infectious agents such as COVID-19.
-
NewsStudy reveals harmful gut bacteria linked to irregular sleep patterns
New Study from King's College London: Irregular Sleep Patterns Tied to Harmful Gut Bacteria.
-
ArticleCancer metastasis: breakthrough in therapeutic strategies
A new discovery from the University of Southern California (USC) on cancer metastasis has opened up new possibilities for combating the spread of this devastating disease.
-
NewsCracking the code of influenza evolution
Researchers provide new insights into viral evolution and have significant implications for understanding and predicting the behaviour of influenza and other mutating diseases.
-
ArticlePrecision medicine: exploring the impact of DNA Testing
The potential of precision medicine requires a small shift in perspective, Patrick Short, CEO and co-founder of Sano Genetics, explains in this Q&A.
-
News
Novel vaccine key to reduce Alzheimer’s impact
Promising preliminary research reveals a novel vaccine targeting an Alzheimer’s disease-related protein successfully eliminated toxic cells in mice afflicted with the condition.
-
ArticleWomen in STEM with Michelle Arkin
Join us for our monthly Women in STEM series where we showcase and celebrate the achievements of inspiring women in the field. Step into the world of scientific innovation with Michelle Arkin, a visionary chemical biologist who leads the way as a Professor and Chair of Pharmaceutical Chemistry at UCSF. ...
-
ArticleGenetic variant identification: unveiling the power of STING-seq
In an exclusive interview, Dr Neville Sanjana, Associate Professor of biology at NYU and a core faculty member at the New York Genome Center, discusses the breakthrough study on STING-seq.
-
ArticleLong COVID breakthrough
In this Q&A, Dr Steve Gardner elucidates the genetic variations that appear to underpin the debilitating new condition, long COVID, that have been uncovered in a recent analytical study.
-
ArticleBiochemical assays and deep cyclic inhibition in cancer treatment
Drug Target Review's Taylor Mixides exclusively interviews Brett Hall, Chief Scientific Officer at Immuneering, about his company’s aim to develop a universal-RAS therapy.
- Previous Page
- Page1
- Page2
- Page3
- Page4
- Next Page